Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)

4.24
Delayed Data
As of Aug 28
 -0.07 / -1.62%
Today’s Change
2.96
Today|||52-Week Range
9.32
-37.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$188.2M

Company Description

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of actual pain. Its lead product candidate includes ZalvisoTM intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system. It is designed to address the problems associated with post-operative intravenous patient-controlled analgesia, or IV PCA. AcelRx Pharmaceuticals was founded by Thomas A. Schreck and Pamela P. Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Contact Information

AcelRx Pharmaceuticals, Inc.
351 Galveston Drive
Redwood City California 94063
P:(650) 216-3500
Investor Relations:

Employees

Shareholders

Other institutional30.14%
Individual stakeholders29.67%
Mutual fund holders11.47%

Top Executives

Howard B. RosenChief Executive Officer & Director
Timothy E. MorrisCFO & Head-Business Development
Pamela Pierce PalmerDirector & Chief Medical Officer
Mark A. EvashenkVice President-Clinical Operations
Carter J. KingVice President-Corporate Development